Brief: Everest Medicines Enters Agreement For Exclusive LNZ100 License In Greater China
08/06/2026 02:27
BRIEF-Everest Medicines Enters Agreement For Exclusive LNZ100 License In Greater China June 8 (Reuters) - Everest Medicines Ltd 1952.HK:
ENTERS AGREEMENT FOR EXCLUSIVE LNZ100 LICENSE IN GREATER CHINA
TO PAY UPFRONT, MILESTONE PAYMENTS AND TIERED ROYALTIES FOR LNZ100
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region